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ABSTRACT OF THE DISSERTATION 
Controlling the Oxygen Microenvironment: The Role of HIF-1α in Early Tumor Progression 
by 
Sandra Lam 
Doctor of Philosophy in Biomedical Engineering 
Washington University in St. Louis, 2018 
Professor Steven George, Chair 
Professor Lori Setton, Co-Chair 
 
Cancer drug efficacy has remained a critical obstacle for researchers as it has one of the lowest 
probabilities of success compared to other diseases. One method to help improve this success 
rate is to create better tumor models on which to perform the drug testing. With growing 
interesting in microphysiological systems, scientists can create more advanced in vitro models of 
human organ systems as well as diseased states. These “organ-on-a-chip” platforms aim to 
improve drug response prediction for both efficacy and toxicity. One underappreciated 
characteristic of many disease states is that they are often at a lower oxygen tension that normal 
tissue (a condition known as hypoxia). Not only is this the case for cancer, but it is thought to be 
one of the main reasons why cancer treatment fails. Furthermore, cancer can experience two 
types of hypoxia: chronic (sustained low oxygen tension) or intermittent (varying cycles of 
hypoxia and normoxia). In both conditions, the vasculature determines the spatial and temporal 
dynamics of oxygen. If the tumor cells expand far enough away from the vasculature, this 
diffusion-limited oxygen condition will lead to chronic hypoxia. On the other hand, if the tumor 
cells encourage rapid vasculature growth that tends to be tortuous and leaky, then this will lead 
to intermittent hypoxia. Under both hypoxic conditions, tumor cells upregulate hypoxia inducible 
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factor 1α (HIF-1α), a transcription factor which affects many downstream processes that 
encourages cell survival. In this dissertation, we investigate our ability to use a microfluidic 
platform to mimic some of these key features in the hypoxic tumor microenvironment and test if 
it can recapitulate some known biological responses.  
First, we created a microfluidic device that can control both spatial and temporal 
gradients of oxygen via an oxygen scavenger line. As tumor angiogenesis is a major concern 
during tumor progression, we examined angiogenesis in the device. Vasculature was grown in   
the central chamber of the device, and stromal cells were grown in compartments on both sides 
of the vasculature. Lastly, the oxygen scavenger was flown in a channel adjacent to the left 
stromal chamber to create an oxygen gradient across the device. By controlling the flow the of 
oxygen scavenger, we could simulate both chronic and intermittent hypoxia. Our results 
demonstrate that stromal cells under hypoxia conditions encourage biased angiogenesis, which is 
in agreement with previous studies.  
Second, using our microfluidic device platform, we investigated how knocking down HIF-1α 
affects the survival and progression of breast cancer cells (MDA-MB-231) under various oxygen 
gradients. By varying the scavenger concentration, we found a threshold for chronic hypoxia that 
the knockdown cells could no longer survive. Interestingly, by modulating the length of the 
hypoxic and normoxic cycles during intermittent hypoxia, we could dictate tumor cell survival. 
This result emphasizes the importance of understanding the temporal variations of oxygen, 
especially with cancer treatments that target HIF-1α.  
Altogether, our results further our understanding of how to control spatial and temporal oxygen 
gradients for disease modeling. Hopefully with this understanding, future studies will be able to 
more effectively assess drug efficacy. 
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Chapter 1: Background and Motivation 
Cancer is the second leading cause of death in the United States of America behind heart 
disease.1 While the number of deaths from heart disease has decreased ever since 1985, the 
number of deaths from cancers has nearly tripled since 1960.2 In addition, it has been estimated 
that the National Cancer Institute (NCI) alone receives more than $5 billion dollars in 
government funding yearly.3 However, there has yet to be a cancer treatment that is effective for 
all patients. Meanwhile, the cost of developing a pharmaceutical drug is on the rise; the current 
estimate is $1.3 to $2.6 billion to develop a single drug approved by the US Food and Drug 
Administration (FDA).4,5 One solution to curb the rising development costs is to create better 
models for drug testing.5  
There are many difficulties associated with mimicking the tumor microenvironment. Perhaps the 
most important is the shear complexity of the tumor microenvironment; that includes an array of 
cell types.  For example, there is close interaction between the growing tumor and vasculature. 
While angiogenesis remains quiescent for the most part in adults, in tumor progression, the 
“angiogenesis switch” remains on constantly.6 This is because the rapidly growing tumor 
requires nutrients and oxygen as well as to discard metabolic byproducts and carbon dioxide. 
Furthermore, access to a vascular network provides tumor cells a method for intravasation and 
metastasis.7 These instances are of particular interest to study because the five-yea survival rate 
of patients with breast cancer metastasis drop dramatically to 22%.8  
To promote tumor angiogenesis, as the tumor grows, it further depletes oxygen via cellular 
consumption. This condition of low oxygen (hypoxia) is often associated with poor patient 
outcome.9 While a normal tissue response is cellular necrosis, cancer cells have developed an 
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adaptive mechanism that allows them to thrive in hypoxia.10 In addition, advanced cancer is 
typically associated with an oxygen tension that is much lower than normal physiology.10 Under 
this condition, cancers tend to resistant to traditional cancer treatments such as chemotherapy and 
radiotherapy. This effect has largely been attributed to the stabilization of transcriptional 
regulator, hypoxia-inducible factor 1-alpha (HIF-1α).11 In cancer biology, this transcription 
factor is often dysregulated and overexpressed. Thus, one strategy to develop effective cancer 
treatments in a more efficient manner is to replicate this hypoxia microenvironment during drug 
testing.9  
There are several reasons why it is difficult to replicate the oxygen gradients in the tumor 
microenvironment. First, normal physiology is around 5% O2, the hypoxic tumor 
microenvironment can be less than 1% O2, and atmospheric oxygen is about 20% O2.
12 This 
means that cell cultures grown at atmospheric oxygen are experiencing hyperoxia. Second, some 
research groups choose to set their incubators to a hypoxic oxygen tension, such as 1% O2. 
However, this approach does not have the ability to create and control spatial oxygen gradients 
that are present in normal physiology.13 Lastly, another strategy to studying hypoxia is to use a 
compound such as cobalt chloride that will stabilize HIF-1α during normoxia.14,15 While this 
makes working with the cell cultures easier, it limits the study to only those signaling 
mechanisms that are downstream of HIF-1α. In addition, this method also does not replicate the 
oxygen gradients are present during tumor progression.  
Furthermore, while few studies observe the effects of true hypoxia, most only focus on chronic 
hypoxia (sustained low oxygen tension) and not intermittent hypoxia (cycles of hypoxia and 
normoxia). However, it has been hypothesized that intermittent hypoxia is more representative of 
the tumor microenvironment due to the abnormalities of the vasculature due to rapid 
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angiogenesis.16 However, this phenomenon has been severely underappreciated due to the 
difficulties in not only controlling the spatial distribution of oxygen, but the temporal distribution 
as well.  
One potential solution to recapitulating the oxygen dynamics of the tumor microenvironment is 
to use microfluidic devices. Typically, this type of device will have a scavenger channel 
dedicated to introducing an oxygen scavenger near the tumor culture chamber. This creates an 
oxygen sink that will draw oxygen away from the tissue culture. Additionally, due to their 
inherently small size, diffusion is rapid allowing specified oxygen gradients to be precisely 
controlled spatially and temporally. This type of platform allows for growing 3D cell culture as 
well as the ability to include different cell types. By utilizing these aspects of microfluidic 
devices, the microenvironment during tumor progression can be closely recapitulated.  
The dissertation contains 4 subsequent chapters. Chapter 2 overviews the current trends and 
technologies of tumor hypoxia systems, with an emphasis on tumor development. Chapter 3 
focuses on the development of a microfluidic devices to manipulate oxygen tensions within a 3D 
tissue to study hypoxia induced angiogenesis. Chapter 4 examines the role of HIF-1α in tumor 
cells during spatial and temporal variations in hypoxia. Lastly, chapter 5 remarks on future 
advances that can significantly advance the current state of studying tissue hypoxia. 
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Chapter 2: Hypoxia and Tumor Angiogenesis 
2.1 Overview 
The deficiency of oxygen, an essential nutrient for cell proliferation and survival, is a critical 
stimulus for acquiring new blood vessels. Hypoxic tumors activate molecular programs that lead 
to secretion of proangiogenic factors by the tumor as well as tumor-associated stromal cells. 
Tumor hypoxia has been associated with poor patient prognosis, with clinical studies showing 
that advanced breast cancers have a median oxygen tension of 10 mmHg, compared with 65 
mmHg in normal breast tissue.10,17,18 Hypoxic cores exist in advanced stage tumors,19 and can 
also exist in tumors as small as 400 m in diameter.20 In hypoxic conditions, angiogenesis is 
primarily regulated by hypoxia inducible factors (HIFs). Of the highly conserved HIF family of 
transcription factors, HIF-1 has been the best studied.11,21,22 It is known to be a heterodimer of α-
subunit (HIF-1α) and a β-subunit (HIF-1β), where subunits are members of the basic helix-loop-
helix (bHLH)-containing PER-ARNT-SIM (PAS) domain family of transcription factors. In 
addition to HIF-1α and HIF-1β, there are two additional oxygen regulated α-subunits are (HIF-
2α and HIF-3α) and two other constitutively expressed β-subunits (HIF-2β, and HIF-3β). 
Furthermore, the low oxygen environment stabilizes HIF-1α in endothelial cells as well.23 
The HIF-1 activation follows a series of molecular events. Starting at oxygen concentrations 
below 6%, HIF-1α stabilizes and translocates from the cytoplasm to the nucleus, where it 
dimerizes with HIF-1β.24 HIF-1 then binds to hypoxia responsive elements (HREs) within the 
promoters of HIF target genes leading to the increased expression of proangiogenic factors such 
as vascular endothelial growth factor (VEGF), VEGF-R2, angiopoietin 1/2, fibroblast growth 
factor, platelet-derived growth factor, and the decreased expression of anti-angiogenic factors 
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such as thrombospondin-1 and carbonic anhydrase-9.25 In addition to angiogenesis, HIF-1 can 
activate more than a hundred genes that control important cellular processes such as epithelial-
mesenchymal transition, stem-cell maintenance, and metabolism that impact tumor cell invasion, 
metastasis, metabolic reprograming, and resistance to therapy.22  
2.2 Controlling and Measuring Oxygen in vitro 
The traditional method to create hypoxic conditions utilizes cell culture incubators, where 
blending excess nitrogen with air lowers oxygen concentration. Alternatively, the exchange of 
oxygen from air can be controlled by an air tight glove box equipment, or hypoxic conditions can 
simply be generated due to consumption of oxygen by cell culture. Additionally, chemicals that 
consume oxygen, such as sodium nitrate, can also be used to manipulate oxygen tension.12  
Alternatively, cobalt chloride can stabilize HIF-1α in the presence of normoxia, and allows for 
more flexible data collection. This “pseudo-hypoxic” condition can simulate the impact of HIF-
1α, but cannot fully recapitulate all features that hypoxia has on cell function.15  
Microfluidic devices have become attractive systems to study hypoxia due to their inherently 
small size, and thus small diffusion distances. A common technique to reduce oxygen in 
microfluidic devices is to use separate channels containing an oxygen scavenger such as sodium 
nitrate (Fig. 2. 1A). These channels are separated from the tissue chambers by a semipermeable 
material, such as PDMS, that allows diffusion of oxygen but not water.26–28 By altering the 
concentration and flow of the scavenger, the oxygen tension within the device can be controlled 
with high spatial and temporal resolution. PDMS is ideally suited as a material of construction 
for these device as it is a highly permeable material with respect to oxygen compared to 
relatively impermeable  materials such as cyclic olefin copolymer, polystyrene, polypropylene, 
poly(methacrylic acid), polyurethane, and poly(methyl pentene).29 By choosing an appropriate 
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coating and/or using an oxygen scavenger, a wide range of oxygen concentrations can be 
controlled to study tumor hypoxia and its effects.  
A major advantage of using in vitro systems is that real time oxygen measurements can be 
performed in a live tissue culture with minimal disruption of biological processes. The gold 
standard for the oxygen sensors is Clark-type electrodes which measure oxygen by detecting a 
current flow caused by the reduction of oxygen.30 However, the method is operationally complex 
and less sensitive for oxygen measurement relative to other methods.  Recently, more sensitive 
techniques have been developed that employs an oxygen sensitive luminophore. The 
luminescence of oxygen sensitive dyes is inversely proportional to the concentration of oxygen. 
When the dyes are excited by a laser in the presence of oxygen, the excited state energy of the 
phosphorescent indicator molecule is absorbed by oxygen instead of being emitted as a 
luminescent photon. In other words, oxygen quenches the phosphorescence, and reduces the 
lifetime of the phosphorescence decay. Generally, a shorter luminescence lifetime indicates a 
higher oxygen concentration. The lifetime of the phosphorescence, as opposed to the intensity, is 
a more robust method as it is insensitive to photobleaching and independent of the concentration 
of the dye. Detecting the luminescence lifetime generally requires a more complicated 
experimental setup because a pulsed laser needs to be used (Fig. 2. 1B).31  
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While many research groups have focused on controlling the oxygen environment around tumor 
spheroids, some groups, including ours, have begun to control oxygen tension in vascularized 
tumors.26,27,32 Due to the role that the vascular network has in oxygen regulation and the 
interaction between the tumor and the vasculature during hypoxia, the inclusion of these 
components in the next generation of tumor organoid models is critical for a complete 
understanding of angiogenesis in the tumor microenvironment.  
Fig. 2. 1 (A) Oxygen scavenger lines can be designed into microfluidic platforms to generate hypoxic conditions inside tissue 
chambers. Typically these include materials such as sodium sulfite. (B) PhLM is a method used to measure oxygen 
concentrations in 3D culture systems. Using a pulsed laser to excite the oxygen sensitive dye and measuring the dye’s lifetime 
of decay, a longer phosphorescent lifetimes correspond to lower oxygen concentrations.  
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Chapter 3: Microfluidic device to attain high 
spatial and temporal control of oxygen 
3.1 Abstract 
Microfluidic devices have been successfully used to recreate in vitro biological 
microenvironments, including disease states. However, one constant issue for replicating 
microenvironments is that atmospheric oxygen concentration (20% O2) does not mimic 
physiological values (often around 5% O2). We have created a microfluidic device that can 
control both the spatial and temporal variations in oxygen tensions that are characteristic of in 
vivo biology.  Additionally, since the microcirculation is responsive to hypoxia, we used a 3D 
sprouting angiogenesis assay to confirm the biological relevance of the microfluidic platform. 
Our device consists of three parallel connected tissue chambers and an oxygen scavenger 
channel placed adjacent to these tissue chambers. Experimentally measured oxygen maps were 
constructed using phosphorescent lifetime imaging microscopy and compared with values from a 
computational model. The central chamber was loaded with endothelial and fibroblast cells to 
form a 3D vascular network. Four to six days later, fibroblasts were loaded into the side 
chambers, and a day later the oxygen scavenger (sodium sulfite) was flowed through the adjacent 
channel to induce a spatial and temporal oxygen gradient. Our results demonstrate that both 
constant chronic and intermittent hypoxia can bias vessel growth, with constant chronic hypoxia 
showing higher degrees of biased angiogenesis. Our simple design provides consistent control of 
spatial and temporal oxygen gradients in the tissue microenvironment and can be used to 
investigate important oxygen-dependent biological processes in diseases such as cancer and 
ischemic heart disease. 
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3.2 Introduction 
Although hypoxia, or low oxygen tension, is a central feature of many different diseases, it is 
also a part of normal physiological states.10,25,33 Hypoxia can be chronic (sustained oxygen 
tension < 5% O2 for > 24 hours), as in the case of ischemic heart disease and wound healing, or 
intermittent (repeated oxygen tension <5% O2 for < 24 hours) as in the case of some tumors, 
sleep apnea, and exercise.34–37  Moreover, diseases such as cancer can exhibit both chronic 
hypoxia and intermittent hypoxia states which can affect different processes of tumor 
progression. The rapid rate of diffusion of abundant oxygen in gas and liquid systems has made 
it difficult to experimentally study the impact of hypoxia at small spatial scales, in particular, to 
replicate in vivo intermittent hypoxia conditions. The presence of atmospheric air (ambient pO2 
is around 160 mmHg or 20% O2) provides a regular source of “contamination” as normoxia or 
physiological oxygen concentration for tissues are on average about 38 mmHg or 5% O2.  
Although previous literature has defined normoxia as 20% O2, we choose to define it as 5% O2 
because it is more physiologically relevant. Although the incubator oxygen tension may be set to 
5% O2, controlling the spatial distribution of oxygen within the cell culture is not possible. As 
the tissue expands farther away from the vessel network, an oxygen gradient is established, with 
the cells farthest away experiencing the lowest oxygen tension. In addition, it has been shown 
that gradients are important for chemical and mechanical factors for recapitulating the 
physiological microenvironment.38,39 
Here, we present a microfluidic device that can precisely control oxygen tension over spatial and 
temporal dimensions on the order of microns and minutes, respectively.  This level of control 
permits the interrogation of physiologically relevant hypoxia in a wide range of normal and 
diseased tissues. Our strategy leverages the small dimensions of microfluidic devices that 
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minimize the distance of diffusion for oxygen to control precise gradients. Microfluidic systems 
provide faster oxygen cycle switching than some commercial systems, (e.g., Eppendorf Galazy 
48R), which can take up to 30 minutes to equilibrate to a new oxygen concentration. In addition, 
previous methods of studying hypoxia in microfluidic devices often involve nearby channels to 
flow nitrogen gas to create an oxygen sink.26,40,41 While this can create controlled oxygen 
gradients, the need for nitrogen tanks is cumbersome. Furthermore, the use of a compressed gas 
can introduce bubbles and pervaporation in the culture chambers, which can compromise the 
experimental conditions. 
Our approach utilizes a simple and inexpensive aqueous solution of sodium sulfite as an oxygen 
scavenger to reduce pervaporation and cost while still maintaining high spatial and temporal 
control of oxygen. This easily prepared solution is flowed in a fluidic channel running parallel to 
the tissue chambers. Because this channel is not connected to the tissue chambers the oxygen 
scavenger will not produce any unwanted side effects to the tissues. Moreover, most in vitro 
studies mimic intermittent hypoxia cycle between 20% and 1% O2 to ensure two different 
oxygen states.42–44 However, 20% O2 is representative of hyperoxia and does not accurately 
represent in vivo intermittent hypoxia. Subsequently, because we can measure the spatial and 
temporal oxygen distribution within our device, we can easily switch between the more 
physiological concentration of 5% and 1% O2. Thus, we believe that our results more accurately 
represent physiological response to intermittent hypoxia. Furthermore, although previous studies 
have shown the effects of using an oxygen scavenger in a 20% O2 incubator the range of oxygen 
concentrations often go far above physiological values.45  
To demonstrate the biological relevance of our microfluidic system, we used an in vitro model of 
angiogenesis. During hypoxia, new blood vessels can sprout from existing vessels (angiogenesis) 
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as a normal biological response to relieve hypoxia by increasing blood flow and delivering 
oxygen. On the other hand, hypoxia can also lead to necrosis of the tissue if there is a failure to 
encourage new vessel growth. These two drastically different outcomes are both possible during 
hypoxia because both pro-angiogenic and anti-angiogenic genes can be activated, and this 
balance dictates the outcome.46 Thus, it is important to determine the subtleties of spatial and 
temporal variations in oxygen and how this can bias vessel growth. Our theoretical and 
experimental results demonstrate spatial and temporal control over the oxygen tension within a 
microfluidic platform. In addition, the simple and flexible design will prove useful for a range of 
additional biological applications. In this study we show the effects of normoxia (N), constant 
chronic hypoxia (CH), and intermittent hypoxia (IH) on true 3D angiogenesis. 
3.3 Materials and Methods 
3.3.1 Design and microfabrication of microfluidic device   
The microfluidic device design has three parallel chambers connected through capillary burst 
valves measuring 30 μm wide and 100 μm high to facilitate communication between chambers 
(Fig. 3. 1A). The central compartment (vascular chamber) is the largest with a volume of 0.06 
mm3 (1.5 mm x 0.4 mm x 0.1 mm), and the two adjacent chambers are smaller with a volume of 
0.02 mm3 (0.8 mm x 0.25 mm x 0.1 mm). Only the central compartment has media lines that are 
connected through capillary burst valves on each end. This design allows for separate chambers 
to contain different compositions of cells and extracellular matrix as well as to be loaded into the 
device at different time points. The two media lines were designed to control the flow of media 
via a difference in hydrostatic pressure head between the two lines. The flow was controlled to 
mimic physiological fluid velocities of approximately 1-10 μm s-1. Lastly, microfluidic channels 
adjacent to each of the smaller tissue chambers are present and are used to deliver the oxygen 
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scavenger to create the oxygen gradient. The microfluidic device design has three parallel 
chambers connected through capillary burst valves measuring 30 μm wide and 100 μm high to 
facilitate communication between chambers (Fig. 3. 1A). The central compartment (vascular 
chamber) is the largest with a volume of 0.06 mm3 (1.5 mm x 0.4 mm x 0.1 mm), and the two 
adjacent chambers are smaller with a volume of 0.02 mm3 (0.8 mm x 0.25 mm x 0.1 mm). Only 
the central compartment has media lines that are connected through capillary burst valves on 
each end. This design allows for separate chambers to contain different compositions of cells and 
extracellular matrix as well as to be loaded into the device at different time points. The two 
media lines were designed to control the flow of media via a difference in hydrostatic pressure 
head between the two lines (Fig. 3. 1B). The flow was controlled to mimic physiological fluid 
velocities of approximately 1-10 μm s-1. Lastly, microfluidic channels adjacent to each of the 
smaller tissue chambers are present and are used to deliver the oxygen scavenger to create the 
oxygen gradient.  
 
A B 
500 μm 
Fig. 3. 1 Microfluidic Device Schematic. (A) The design of the microfluidic device with the central vascular 
chamber (yellow) and adjacent stromal chambers (brown). Scavenger channels (blue) are placed next to the stromal 
chambers and media lines (red) feed the vascular chamber. (B) Experimental setup for the microfluidic devices. A 
difference in hydrostatic pressure head between the inlet and outlet of each microfluidic line creates a drop in 
pressure between the two sides of the vascular chamber to induce convective interstitial flow throughout the device. 
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Once a computer-aided design (CAD) of the device was created, the design was printed and 
standard photolithography methods were used to build the device. Briefly, a negative photoresist, 
SU-8 3050, (MicroChem, Newton, MA) was spun onto a silicon wafer to a height of 100 μm. 
Ultraviolet light exposure crosslinked the pattern of the device into the photoresist. After the 
pattern on the wafer was developed, the mold was silanized and polydimethylsiloxane (PDMS; 
Dow Corning, Elizabethtown, KY) was poured over the mold at a mixture of 10:1 (w/w) 
polymer to curing agent. The PDMS was cured in a 65 °C oven overnight.  The PDMS was then 
peeled off the mold and the inlet and outlet holes were punched into the device using an 18 
gauge needle for the tissue chambers and 16 gauge needle for the media and scavenger lines. To 
bond the PDMS device to a glass slide, both pieces were first cleaned to remove debris and then 
plasma treated for 1 minute at 250 mTorr. After plasma treatment, the PDMS device was sealed 
to the glass slide and placed in a 120 °C oven for a minimum of 15 minutes. Lastly, the device 
was sterilized with ultraviolet light before experimentation.  
3.3.2 Numerical Simulations 
To enhance our understanding of interstitial flow and oxygen concentrations within the device, 
we created a computational model of mass and momentum transport using COMSOL 
Multiphysics® 5.2a (Burlington, MA) combined with the CAD model of the device. To simulate 
the flow throughout the device, a 3D steady state solution of the incompressible Navier-Stokes 
equations was calculated using no slip boundary conditions for all the walls. Properties of the 
components of the device are listed in Table 3. 1 and are consistent with previous work. The 
transport of diluted species module was used to model the oxygen gradients throughout the 
device. Initial conditions for oxygen concentrations was set to 5% O2. Using Henry’s law, the 
outer boundaries of the device (PDMS-air interface) were set using the incubator level of 5% O2, 
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and a Michaelis-Menten kinetic equation was used to simulate cellular metabolism of oxygen.47 
The PDMS-media interface was modeled using a pointwise constraint at the boundary in 
accordance with the stiff-spring method.48 A media/PDMS partition coefficient of 0.18 was used 
in the model. The consumption of oxygen through the reaction with sodium sulfite (Na2SO3) was 
used from previously reported findings in the literature.47,49–54 In brief, 1 mole of oxygen (O2) 
reacts with 2 moles of sodium sulfite (Na2SO3) to produce 2 moles of sodium sulfate (Na2SO4) 
with a reaction rate constant, k (Table 3. 1): 
 (Eq. 1) 
Parameter Value Unit Source 
Inlet pressure (high side) 25 mmH2O - 
Outlet pressure (high side) 0 mmH2O - 
Inlet pressure (low side) 10 mmH2O - 
Outlet pressure (low side) 0 mmH2O - 
Fibrin permeability 1.5E-13 m2 22 
Diffusion of oxygen through PDMS 3.55E-9 m2 s-1 25 
Max rate of oxygen metabolism by cells (Vmax) 1.3E-17 mol s
-1 18 
Oxygen consumption at half of Vmax (KM) .008 mol m
-3 18 
Reaction rate constant (k) 5.77E-5 M0.35 s-1 24 
Partition coefficient 0.18 - 19 
Table 3. 1 List of Model Parameters. 
Opposite the oxygen scavenging channel is a channel open to the atmosphere of the incubator, 
and thus set to 5% O2. The computational mesh of the model consists of 700,000-1,000,000 
tetrahedral grid elements. For the intermittent hypoxia simulations, time dependent simulations 
were used with hour cycles of flowing and stopping the reaction with sodium sulfite. To 
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demonstrate the ability of the device to manipulate the gradient and oxygen tension, additional 
conditions were modeled to create several unique oxygen profiles. The simulated conditions 
(Table 3. 2) include modifying the constant chronic hypoxia condition (CH) to having a reduced 
mass flow rate of the scavenger in the device (rCH), increased wall thickness between the 
scavenger channel and tissue chambers (wCH), and two scavenging lines (2CH). These 
modifications were added to demonstrate the versatility of oxygen gradients available with our 
device. 
Condition Mass Flow 
Rate (mol s-1) 
Wall 
Thickness 
(μm) 
Number of Active 
Scavenger Lines 
Frequency 
(h-1) 
Time during 
cycle (min) 
N 0 - 0 - Constant 
IHon 2 x 10
-6 30 1 0.5 60 
IHoff 2 x 10
-6 30 1 0.5 60 
CH 0.7 x 10-6 30 1 - Constant 
rCH 0.07 x 10-6 30 1 - Constant 
wCH 0.7 x 10-6 60 1 - Constant 
2CH 0.7 x 10-6 30 2 - Constant 
Table 3. 2 List of Experimental Conditions. N: Normoxia; IHon: Intermittent hypoxia while 2 x 10-6 mol s-1 
Na2SO3 is flowing for an hour; IHoff: Intermittent hypoxia while scavenger stopped flowing for an hour; CH: 
Constant chronic hypoxia of flowing 0.7 x 10-6 mol s-1 Na2SO3; rCH: Constant reduced mass flow rate of oxygen 
scavenger flowing at 1/10th the speed of CH; wCH: Constant hypoxia with increased thickness of the PDMS wall 
between the scavenging channel and tissue chamber; 2CH: Constant hypoxia with two active scavenger line 
3.3.3 Oxygen Measurements 
To validate the oxygen concentration predictions from the computational model, we used 
phosphorescent lifetime imaging microscopy (PhLIM) that utilizes an oxygen sensitive dye, 
Oxyphor G4 (Oxygen Enterprises, Philadelphia, PA).31,55 This Pd-tetrabenzoporphyrin based dye 
is based on phosphorescence quenching, and we have already demonstrated its proficiency in an 
in vivo model.56 To excite the phosphorescent dye, we used a 635 nm laser to modulate at 1 kHz 
with 5% duty cycle (FV1200 Olympus confocal with ISS (Urbana-Champagne, IL) 
phosphorescent lifetime instrumentation upgrade). The emission beam was collected through a 
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miniTDU that was equipped with two Hamamatsu 7422p-50 detectors, which was coupled 
directly to the confocal head. To perform the oxygen measurement, the dye was added to the 
media of the device at a concentration of 20 μM after the end of the cellular experiment. The dye 
was allowed to equilibrate for at least an hour through the fibrin and tissue in the device. Oxygen 
measurements were made over the entire area of the three chambers for each of the three 
experimental conditions. The phosphorescent lifetime of each pixel was calculated and was then 
converted into oxygen tension using a previously determined calibration curve at 22 oC. 31 The 
advantage of using the PhLIM technique with Oxyphor G4 is that experimental measurements at 
high spatial and temporal resolution can be achieved. 
3.3.4 Cell Culture 
As previously described by our lab 57,58, endothelial colony forming cell-derived endothelial cells 
(ECFC-EC) were derived from cord blood and seeded on 1% gelatin-coated (Sigma-Aldrich, St. 
Louis, MO) flasks and provided with endothelial growth medium-2 (EGM-2; Lonza, 
Wakersfield, MD). Normal human lung fibroblasts (NHLF) were commercially purchased and 
grown in fibroblast growth media (FGM-2, Lonza) before use in the experiments. All cells were 
cultured in a humidified incubator at 37 °C, 5% CO2, and 20% O2 before loaded into the 
microfluidic device.  
To study angiogenesis in the presence of spatial oxygen gradients, transduced ECFC-ECs that 
constitutively express fluorescence were used to continuously monitor growth of new blood 
vessels. To transduce the cells, we used a lentiviral particle titer from a human embryonic kidney 
primary cell line (HEK293T Cells, ATCC, Manassas, VA). The HEK293T cells were seeded in a 
6 well plate at a density of 5.0 x 105 cells/well and incubated for 24 hours in Dulbecco’s 
Modified Eagle Medium (DMEM, ThermoFisher, Waltham, MA) containing 10% fetal bovine 
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serum (FBS, Sigma-Aldrich, St. Louis, MO) and no antibiotics. A solution of 250 μL of Opti 
MEM (Invitrogen, Carlsbad, CA), 7.5 μL of Lipofectamine 2000, and 3μg of plasmid DNA (1.5 
μg pLVX-Azurite, .75 μg pMDLg/pRRE, .3 μg pRSV-Rev, and .45 μg pMD2.G) was mixed and 
incubated for 25 minutes at room temperature. Then, 500 μL of the solution was added dropwise 
to the wells of the HEK293T cells. The contents of each well was replaced with fresh media 24 
hours later. After 48 hours of incubation, the viral supernantant was collected and spun down to 
exclude cell debris and stored at -80 °C. A T-150 flask of ECFC-ECs were seeded and grown 
until about 30-40% confluency. Then, a 25 mL solution of EGM containing 8 μg/mL polybrene 
(Santa Cruz Biotechnology, Dallas, TX) and 500 μL of viral titer was added to the cells and 
allowed to incubate for 24 hours at 37 °C. The contents of the flask were then aspirated and fresh 
EGM was added. Transduction efficiency was measured to be more than 90%.  
3.3.5 Device Experimentation 
For the vascular chamber, ECFC-ECs and NHLFs were trypsinized and resuspended in 16 mg 
mL-1 bovine fibrinogen (Sigma-Aldrich, St. Louis, MO) dissolved in Dulbecco’s Phosphate 
Buffered Saline (DPBS; ThermoFisher). The ECFC-ECs were collected at 5 x 106 cells mL-1 and 
the NHLFs were collected at 10 x 106 cells mL-1. Thrombin (Sigma-Aldrich) was prepared to a 
concentration of 50 U mL-1 in DPBS and added to the cell-fibrinogen solution. This initiated the 
polymerization process, and the solution was quickly pipetted into the central or vascular 
chamber of the device. After incubating the gel for 30 minutes at 37 °C, EGM-2 was added to the 
media lines for the first 24 hours of the experiment and flow was maintained using a hydrostatic 
pressure head. Afterwards, the devices were placed in a 37 °C, 5% CO2, and 5% O2 incubator 
and EGM-2 without growth factors was used to feed the tissue. The direction of the pressure 
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gradient throughout the device was switched every day to ensure spatially homogenous growth. 
59,60 
Following the first four days of the experiment, vascular structures were apparent, and the 
adjacent chambers were then loaded with fibroblasts in a fibrin gel at a concentration of 7.5 x 106 
cells mL-1 using the previously described method. After 24 hours, the oxygen scavenger, sodium 
sulfite (Sigma Aldrich, St. Louis, MO), was dissolved in deionized water and pushed through the 
left scavenger channel of the device using a syringe pump. Only one of the scavenging channels 
had an oxygen scavenger flowed through it. The other channel (farthest right channel) was kept 
open to atmosphere to keep the right tissue chamber close to normoxia. Tygon tubing (Saint-
Gobain, Valley Forge, PA) was used to connect the sodium sulfite syringes with the devices. To 
ensure that the two hypoxia conditions had the same average oxygen concentration over the 
duration of the experiment, 0.35M sodium sulfite was flowed at 120 μl min-1 (mass flow rate of 
0.7 x 10-6 mol s-1) continuously for the CH condition while 1 M flowed at 120 μl min-1 (mass 
flow rate of 2 x 10-6 mol s-1) was used for the IH condition with the pump programed for 1 hour 
of scavenger flow (IHon) and 1 hour of no flow (IHoff). To mimic CH and IH, sodium sulfite was 
introduced through the left side of scavenger line for 6 more days until the end of the duration of 
the experiment. Because sodium sulfite constantly reacts with oxygen, it was important to 
maintain a constant flow of oxygen scavenger. 
3.3.6 Quantification of Biased Angiogenesis 
At the end of the experiment, images were taken of the fluorescent vascular network in each of 
the chambers. To quantify sprouting angiogenesis, images were cropped to only contain the left 
or right stromal chamber. The images were randomized and blinded for image analysis in 
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ImageJ. Multiple devices were used for each condition of N (n=8), CH (n=11), and IH (n=17). 
We calculated biased angiogenesis using the following relationship: 
               (Eq. 2) 
In other words, the vessel area in each side chamber is expressed as the fraction of total 
angiogenesis into both chambers. A value of 0.5 indicates unbiased angiogenesis. 
3.3.7 Statistical Analysis 
Because the data was not normally distributed, the parameters are presented with medians and 
ranges from the 25% to 75% percentile. To determine if the biased angiogenesis and vessel area 
in the left chamber was significantly different compared to the right chamber, a nonparametric 
Mann-Whitney test was applied using GraphPad Prism. Significance was determined at the p < 
0.05 level.  
3.4 Results 
3.4.1 Microfluidic Device: Pressure and Flow   
After successful construction of the microfluidic device, we demonstrated desired pressure and 
velocity profiles (Fig. 3. 2A-B). The steady pressure profile of the device (Fig. 3. 2A) 
demonstrates a drop in pressure in the vascular chamber to the stromal chambers from 1 x 10-2 
mmH2O to 0.5 x 10
-2 mmH2O (approximately 9.8 x 10
-2 to 4.9 x 10-2 Pa), respectively, with the 
stromal chamber averaging 0.85 x 10-2 mmH2O (8.3 x 10
-2 Pa). Additionally, the device was 
designed to create physiologically relevant fluid velocities ranging between 1-10 μm s-1 by 
appropriately adjusting the hydrostatic pressure head (25 mmH2O, Fig. 3. 2). Another design 
consideration to note is that the adjacent stromal chambers do not have separate media lines; the 
chambers receive nutrients through the vascular chamber as shown by the streamlines (Fig. 3. 
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2B). To demonstrate this effect in the device, fluorescein isothiocyanate-dextran (FITC-dextran) 
was introduced through the media lines to show the direction of fluid flow through the 
connecting pores (Fig. 3. 2C). 
 
3.4.2 Microfluidic Device: Oxygen Concentration Profiles 
Each experimental condition was modeled using a 3D simulation, and 2D projections are shown 
from a slice of the model in the xy plane 50 μm from the bottom of the device (plane at vertical 
center). In addition, a horizontal line (represented by a white arrow) was drawn in the middle of 
the chambers to quantify the gradient across the device (Fig. 3. 3A-C, top row). With no 
scavenger present (N condition) the oxygen concentration remains constant near 5% O2 
throughout the device (Fig. 3. 3A, top, and Fig. 3. 3E). Although the device is fairly symmetric, 
the placement of the media lines on the left side of the central chamber (Fig. 3. 1A) raises 
oxygen tension slightly in the left stromal chamber. The CH condition (0.7 x 10-6 mol s-1 sodium 
sulfite) created a steady state oxygen gradient from 3.2% O2 in the left chamber to 4.6% O2 in 
the right chamber (Fig. 3. 3B, top, and Fig. 3. 3E), and a mean concentration of 4% O2 in the 
central chamber. 
 
 
Fig. 3. 2 Microfluidic Device Characterization. (A) Surface map of the steady pressure (Pa) distributions inside the 
microfluidic device. (B) Surface map of the fluid velocity (μm s-1) and streamlines. (C) FITC-dextran was 
introduced through the media l nes to de onstrate the direction of flow through the device (bottom to top and 
central chamber to outside chambers).  The image was taken 30 minutes after introducing the dye. Scale bar = 200 
μm. 
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Fig. 3. 3 Finite Element Simulations and Measurements of Steady State Oxygen Tension. (A-C, top row) Surface maps 
of theoretical oxygen tension in different conditions are shown. (A) Normoxic condition (N) with no oxygen scavenger, 
(B) constant chronic hypoxia condition (CH) with a constant flow of 0.35 M sodium sulfite flowing at 120 μl min-1, and 
(C) intermittent hypoxia (IH) condition of alternating 1 M sodium sulfite flowing at 120 μl min-1 for an hour (IHon, left 
panel) and no flow of oxygen scavenger for an hour (IHoff, right panel). (A-C, bottom) Experimental oxygen maps were 
constructed using a PhLIM technique for the N (A, bottom), CH (B, bottom), and IH (C, bottom) conditions. The IHon 
measurements were taken an hour after flowing sodium sulfite, and the IHoff measurements were taken an hour after 
stopping flow. (D) Temporal variations of the oxygen tension at a point in the left stromal chamber from the COMSOL 
model in (C, top). The asterisks (*) and circle (o) on the oxygen maps corresponds to the low and high points of the 
graph, respectively. (E) Comparing the oxygen profiles of all the varying conditions along the central line of the three 
chambers (arrow in A-C). The conditions are N (black), CH (red), IH (green). The IH case is represented by a green area 
to illustrate the range of oxygen profiles between the two extreme states of the condition. The solid lines are values from 
the COMSOL model, and the points are averages from the PhLIM measurements for the three conditions (n=3 for each 
conditions). 
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The IH condition was designed to have the same average oxygen concentration over time as CH. 
After one hour of 2 x 10-6 mol s-1 sodium sulfite flowing through the scavenger line in the IH 
condition, the oxygen tension ranged from 1.7% (left) to 4.5% (right) O2 (Fig. 3. 3C, top left, 
and Fig. 3. 3E). After one hour of no scavenger flow, the oxygen profile resembled the normoxia 
case with the average concentration being only slightly less than 5% O2 (Fig. 3. 3C, top right, 
and Fig. 3. 3E). The time averaged mean concentration in the central chamber over a complete 
cycle was 4% O2, similar to that of CH. The temporal variations of a fixed position in the middle 
of the left chamber is shown by the * and o symbols in Fig. 3. 3C to demonstrate the dynamics 
in our device (Fig. 3. 3D). This figure also shows the step function of the flow of oxygen 
scavenger going from 120 μl min-1 to no flow. Although the sodium sulfite reacts with oxygen 
quickly to lower the concentration, there is a lag to reach the final oxygen concentration (Fig. 3. 
3D). In these experiments, we used molar concentrations of sodium sulfite to ensure a zero 
concentration of oxygen within the solution. The reaction of sodium sulfite depends only on the 
concentration of sodium sulfite and is zero order with respect to oxygen53; thus, the aqueous 
solution of sodium sulfite quickly (minutes) depletes all the oxygen before entering the 
microfluidic device. This makes sodium sulfite a very effective solution for creating hypoxic 
oxygen gradients.  
Experimental oxygen measurements were taken once the dye reached equilibrium within the 
device. The oxygen maps of the experimental conditions are shown in Fig. 3. 3A-C, bottom, 
with the measurements for the intermittent hypoxia condition taken one hour after each cycle 
began. The experimental oxygen concentrations (mean top to bottom for each location from the 
scavenger) for each condition (Fig. 3. 3E) were in agreement with the simulated values (Fig. 3. 
3A-C, top row).  
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To illustrate the utility of the microfluidic device for different spatial and temporal oxygen 
gradients, we performed three additional simulations (Table 3. 2, Fig. 3. 4). The first condition, 
rCH, consisted of reducing the mass flow rate of sodium sulfite to 1/10th the original speed 
compared to CH (0.07 mol s-1, Fig. 3. 4A) which increases the oxygen concentration (range of 
4.5% to 4.9% O2). Next, the condition wCH manipulated the oxygen profile by changing the 
thickness of the PDMS wall that separates the tissue chambers and the scavenger line. By 
doubling this wall to 60 μm compared to CH (wall thickness of 30 μm), and using the original 
mass flow rate of 0.7 x 10-6 mol s-1, the overall concentration of oxygen was also increased 
(range of 3.4% to 4.7% O2, Fig. 3. 4B). Lastly, the condition 2CH drastically changed the 
oxygen profile by flowing 0.7 x 10-6 mol s-1 sodium sulfite through both scavenger lines. This 
condition lowered the overall concentration of oxygen in the device by scavenging both sides. In 
contrast to all previous simulations, the middle chamber had the highest oxygen concentration as 
it was the furthest from the scavenger lines. The oxygen tension range in this case was 2.4% to 
2.8% O2 (Fig. 3. 4C). The oxygen quantification of each condition is shown in Fig. 3. 4D and 
represents the concentration of oxygen at each distance along the middle of the chamber (arrow 
in Fig. 3. 4A-C). As with the previous simulations, because of the subtle asymmetry of the 
device, the oxygen gradient is not perfectly symmetric although the two scavenger lines have the 
same mass flow rate of sodium sulfite. The simulations show a range of oxygen tensions that can 
be achieved by varying parameters such as oxygen scavenger concentration, time exposed to an 
oxygen scavenger, flow rate of the oxygen scavenger, membrane wall thickness, and number of 
active scavenger lines. 
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3.4.3 Angiogenesis within the three-chambered device 
The ECFC-ECs and NHLFs in the central chamber were allowed to grow in a fibrin gel 
independently for the first four days of the experiment until early vasculature structures were 
apparent. On day 4, NHLFs in a fibrin gel were loaded into the adjacent left and right chambers, 
and after 24 hours of incubation, the NHLFs began to spread and resume normal fibroblast 
morphology. Sprouting vasculature into the left and right stromal chambers was apparent after 6 
days.  
At the end of the experiment, each condition had devices that sprouted vessels into the adjacent 
chambers. Fig. 3. 5A shows representative images of the three conditions at the start (left panels) 
and end (right panels) of the experiment. After images of the left and right chambers were 
randomized and blinded for image analysis, parameters of vessel area and angiogenesis bias were 
Fig. 3. 4 Varying Device Parameters. (A) Reduced mass flow rate condition (rCH) with 0.07 x 10-6 mol s-1 of 
sodium sulfite. (B) Increased wall distance (wCH) between the scavenger channel and stromal chamber to 60 μm. 
(C) Two active scavenger lines (2CH). (D) Comparing the oxygen profiles of all the varying conditions along the 
central line of the three chambers (arrow in A-C) with the experimental conditions from Fig. 3. The conditions are N 
(black), CH (red), IH (green), rCH (yellow), wCH (purple), and 2CH (blue). 
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calculated. In the N condition, the left chamber had an average area of 35,577 (8,034 – 46,742) 
μm2 and the right chamber had an average area of 40,582 (10,109 – 62,537) μm2.  This generated 
values for angiogenesis bias of 0.45 (0.18 – 0.65) and 0.55 (0.35 – 0.82) for the left and right 
chambers, respectively, which were not statistically significant.  In the CH condition, the left 
chamber had an average area of 12,606 (1,644 – 14,696) μm2, which was significantly higher 
than the right chamber with an average area of 1,187 (167 – 2767) μm2, p < 0.05.  This result was 
also present in the angiogenesis bias for the left and right chambers which were 0.93 (0.72 – 1.0) 
and 0.07 (0.0 – 0.28) respectively (p < .0001).  Lastly, the IH case also had significantly different 
vessel areas in the adjacent chambers with the left chamber having an average of 4,664 (3,121 – 
6539) μm2 and the right chamber having an average area of 1,289 (300 – 4970) μm2, p < 0.05 . 
This trend produced an angiogenesis bias of 0.78 (0.51 – 0.96) and 0.22 (0.04 – 0.49) for the left 
and right chambers which was statistically significant (p < .0005) (Fig. 3. 5B-C). 
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We also created control conditions that contained no fibroblasts in the adjacent compartments 
(plain fibrin) under normoxic and constant chronic hypoxic conditions. In the normoxic case, 
there were no angiogenic sprouts into the adjacent chambers. On the other hand, the device with 
plain fibrin in the adjacent chambers had degraded vessels under the constant chronic hypoxic 
condition (data not shown). 
3.5 Discussion 
A promising use of organ-on-a-chip technology is the ability to mimic and test disease states. 
Hypoxia is a prominent feature of diseases such as wound healing, ischemia, and cancer. Hence, 
the ability to control oxygen within a microfluidic device provides a unique opportunity to 
understand the impact of oxygen tension at high spatial and temporal resolution. While common 
previous studies may set an incubator to a specific oxygen concentration, this does not create the 
oxygen concentration gradients that are relevant to human physiology. The structure of the 
microcirculation is sensitive to oxygen tension, and our device design demonstrates the ability to 
spatially (microns) and temporally (minutes) control the oxygen concentration around a steady 
vascular network to study these effects. Our device can introduce various combinations of cells 
and extracellular matrix at different time points as well as manipulate the oxygen concentration 
to simultaneously compare the effects of a normoxic and hypoxic stromal chamber on a 
neighboring vascular network. 
Fig. 3. 5 Biased Angiogenesis Due to Hypoxia. (A) Representative images from the N (top), CH (middle), and IH 
(bottom) conditions. In each category, images of the vascular network before (left) and after (right) the condition 
was applied is shown. (B) The total vessel area for each category in the left and right stromal chambers were 
measured and compared. For both hypoxic conditions, the vessel area in the left stromal chamber (closer to the 
scavenger channel) was significantly higher than the right chamber. (C) Biased angiogenesis was calculated for the 
left and right stromal chambers in each condition and compared to each other. Both hypoxic conditions had 
significantly more bias in the left stromal chamber. N, n=8; CH, n=11; IH, n=17. Scale bar = 200μm * p<.05, ** 
p<.005, *** p<.0005, **** p<.0001. 
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Our ability to experimentally measure oxygen within the device provides the opportunity to 
validate the performance and accuracy of the platform and model simulations.  PhLIM provides 
high spatial resolution in 3D that is capable of capturing an entire oxygen map.   This is a distinct 
advantage over traditional oxygen sensors and probes that are placed on one surface or in a 
single position and rely on models to extrapolate the3D oxygen map.  The PhLIM oxygen 
measurements closely match the oxygen values predicted by the model over a range of 
experimental conditions.  
While other intermittent hypoxia studies typically switch between 20% and 1% O2 
42–44,  it is 
physiologically more relevant to cycle between 5% and 1% O2 to replicate disease states such as 
the tumor microenvironment in the presence of leaky vasculature.10 In our simulations and 
experiments, we are able to easily produce oxygen values in the 1-5% O2 range.  Although we 
only tested one frequency in this study, our device has the ability to recreate longer or more 
extreme hypoxic frequencies. While other studies have found results that may suggest that 
intermittent hypoxia can increase proliferation or migration of fibroblasts, these studies often 
cycle between 20% O2 and 1% O2.
61 Even though we did not see these results in our intermittent 
hypoxia condition, we believe that our results are more relevant to human physiology because 
we chose to cycle between oxygen concentrations that are apparent in vivo. 
To demonstrate the biological relevance of our device, we investigated the ability of constant 
chronic and intermittent hypoxia to stimulate angiogenesis.  In normoxia (5% O2), vessel growth 
was relatively uniform into both adjacent tissue compartments.  Although not statistically 
different, small variances between the left and right compartments could be due to the slight 
asymmetry in the design. Our device was able to recreate sprouting angiogenesis into a hypoxic 
tissue microenvironment under both constant chronic and intermittent conditions. This 
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observation is consistent with a normal biological response.25,61,62 The hypoxic conditions 
generated less total vasculature than the normoxia case.  This can be explained by the lower 
mean oxygen tension within the vasculature chamber of the CH and IH cases (as low as 3.5% 
and 2.5%, respectively, compared to 5%). The lower oxygen tension in the two hypoxic 
conditions likely results in hypoxic stress to the vascular network and reduced overall sprouting. 
The constant chronic hypoxia condition had more significant angiogenesis bias towards the low 
oxygen chamber compared to the intermittent hypoxia condition as well as greater vessel area. 
This is probably due to the range of oxygen concentrations we’ve chosen as well as frequency of 
the cycle. Alternatively, as the constant chronic hypoxia case is a continuous exposure to 
hypoxia, the stressed fibroblasts in the left chamber might have continually expressed pro-
angiogenesis factors to encourage more vessel growth relative to the intermittent hypoxia 
condition. As shown previously by our group, the frequency of the intermittent hypoxia cycles 
can change how a vessel responds, which can be correlated to the amount of vascular endothelial 
growth factor that is secreted by hypoxic fibroblasts.63 
3.6 Conclusion 
The results of this study show the effectiveness of microfluidic devices to control and manipulate 
oxygen tension at high spatial and temporal resolution. The device design demonstrates the 
ability to load different types of cells at different time points, which provides the opportunity to 
model many different normal and pathological states. We chose 3D sprouting angiogenesis to 
demonstrate the biological relevance of the device design, and we were able to replicate the well-
described angiogenic response of hypoxic (constant chronic and intermittent) fibroblasts. The 
simple and flexible design of the devices provides an opportunity to enhance understanding of 
important disease processes present in cancer, ischemic heart disease, and wound healing. 
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Chapter 4: Knockdown of HIF-1α Affects 
MDA-MB-231 Survival under Spatial and 
Temporal Oxygen Gradients  
4.1 Abstract 
The cost of guiding a clinical drug through discovery and development has been on the rise, and 
it is now estimated that one drug can cost as much as $1.3 to $2.6 billion dollars. One method to 
reduce costs is to create better platforms that more accurately replicates human disease 
physiology in the pre-clinical phase to improve the efficiency and success in the clinical trial 
phase.  As cancer is the second leading cause of death in America, the development of new 
therapies remain a priority. It been shown that tumor hypoxia, or low oxygen tension, contributes 
to cancer drug resistance, yet most experiments mimicking cancer drug response are done at 
atmospheric oxygen concentration (20% O2).  This condition is a poor representation of hypoxic 
tumor biology in vivo (< 5% O2). Furthermore, the leaky and tortuous nature of tumor 
vasculature contributes to an oxygen tension that can fluctuate temporally between hypoxia and 
normoxia (5% O2), a condition known as intermittent hypoxia. To replicate these dynamics of 
the tumor microenvironment, we have designed a microfluidic device that can control the spatial 
and temporal gradients of oxygen using an oxygen scavenger, sodium sulfite, to create an oxygen 
sink. The scavenger is placed in microfluidic line next to a tissue chamber that contains MDA-
MB-231 breast cancer cells grown in a fibrin gel. Finite element modeling were used to predict 
the oxygen gradients achieved in the microfluidic device. We knocked down the expression of 
hypoxia inducible factor 1 alpha, the key transcriptional regulator of hypoxia and a common 
therapeutic target of tumor hypoxia, to understand how the tumor cells would survive in an 
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oxygen gradient. We found that both the oxygen concentration and the duration spent at hypoxia 
are critical determinants of tumor cell migration and survival. This study demonstrates that both 
spatial and temporal dynamics of oxygen tension in the tumor microenvironment could impact 
drug efficacy. 
4.2 Introduction 
Hypoxia, or low oxygen tension, has become a hallmark of tumor progression as tumor cell 
proliferation commonly exceeds diffusion of oxygen from the local vascular network creating an 
imbalance of supply and demand. Furthermore, clinical studies showed advanced breast cancer 
having a lower oxygen tension (10 mmHg) than normal breast tissue (65 mmHg).10 
Subsequently, hypoxia has been associated with poor patient prognosis due to gene expression 
changes that tumor cells can undergo during this process. Some processes associated with tumor 
hypoxia are migration, tumor angiogenesis, metabolic reprogramming, cancer stem cell 
maintenance, dormancy, and immune evasion, all which can contribute to treatment 
resistance.64,65 In addition, the heterogeneity of vasculature in the tumor microenvironment can 
lead to instances of intermittent hypoxia of repeated oxygen tension < 5% O2 cycling with 
normoxia. Nevertheless, both chronic (sustained oxygen tension < 5% O2) and intermittent 
hypoxia have been shown to contribute to tumor progression. 
Tumor response to hypoxia is controlled largely by the transcription factor hypoxia-inducible 
factor 1 (HIF-1).22,66 HIF-1 has two subunits (HIF-1α and HIF-1β), and under normal oxygen 
conditions, HIF-1α is rapidly degraded by a family of prolyl hydroxylases. However, when as 
oxygen tension decreases, the action of the prolyl hydroxylases is progressively compromised 
leading to increased levels of HIF-1α in the cytoplasm. HIF-1α is then free to translocate to the 
nucleus where it forms a heterodimer with HIF-1β and binds to the hypoxia responsive elements 
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(HRE) in the promoter region of many genes.  For example, increased levels of HIF-1α can lead 
to enhanced expression of pro-angiogenic factors such as vascular endothelial growth factor 
(VEGF) and VEGFR1, VEGFR2, plasminogen activator inhibitor-1 (PAI-1), angioprotein-2 
(Ang-2), and inducible nitric oxide synthase (iNOS).10 While it has been established that hypoxia 
increases expression of HIF-1α, our understanding of how temporal changes in oxygen tension 
influence HIF-1α is incomplete. Although preliminary data has shown support that cyclic 
hypoxia may increase the presence of HIF-1α, no direct link has been made to hypoxia cycle 
duration or magnitude.67–70 All these studies of various cancer types under intermittent hypoxia 
showed that an increase in HIF-1α expression lead to tumor progression in terms of increased 
tumor angiogenesis, metastasis, or increased stem-like properties due to downstream 
signaling.67–70  
Because HIF-1α plays such an important role during hypoxic tumor progression, it is a potential 
target for tumor treatment. However, this has been met with varying success, likely due to our 
incomplete understanding.71–73  While most studies have examined the degree of hypoxia74–76, we 
hypothesize that temporal variations of oxygen also impact tumor progression. To study this 
hypothesis, we knocked down HIF-1α in breast cancer MDA-MB-231 cells and applied both 
spatial and time varying oxygen concentrations. Our results show that both the spatial and 
temporal gradients of oxygen affect tumor survival and migration of MDA-MB-231, and that this 
response is HIF-1α-dependent. 
4.3 Methods  
4.3.1 Construction of Microfluidic Device  
In this study, we used a three chambered microfluidic device (Error! Not a valid bookmark 
self-reference.). The chambers were connected to each other via capillary burst valves 
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measuring 30 μm wide. The fibrin chamber (central compartment) is the largest with a volume of 
0.06 mm3, and the adjacent tumor chambers (adjacent) are slightly smaller with a volume of 0.02 
mm3. Media lines connect to the central chamber to feed the adjacent tumor chambers, and 
interstitial flow is driven by a hydrostatic pressure head.  Finally, microfluidic channels 100 μm 
wide run parallel to the tumor chambers and are used to deliver the oxygen scavenger to the 
device.  
 
 
After the device design was created in AutoCAD (San Rafael, CA), the design was printed and 
fabricated using standard photolithography methods. Briefly, SU-8 3050 (MicroChem, Newton, 
MA), a negative photoresist, was spun on to a silicon wafer to a height of 100 μm. Using the 
printed design, ultraviolet light was used to crossline the pattern into the photoresist. Next, a 
developer was used to leave the crosslinked pattern on the wafer. This mold was then silanized 
and polydimethylsiloxane (PDMS; Dow Corning, Elizabethtown, KY) was poured over the mold 
at a mixture of 10:1 (w/w) polymer to curing agent. The polymer was then cured at 65 °C for at 
1 2 3 
1: MDA-MB-231 cells 
2: Fibrin 
3. MDA-MB-231 cells 
Fig. 4. 1 Device Schematic. Our device is about the size of a US dime (left image). It consists of three tissue 
chambers (larger brown chambers) and two media lines (smaller brown lines). The outer chambers are loaded with 
MDA-MB-231 cells in gel, and the central chamber is loaded with plain fibrin. Sodium sulfite is convected through 
the scavenger line (blue), while the opposite line (red) is left open to atmosphere. 
33 
 
least two hours. The PDMS was then peeled off and the devices were cut individually. The inlets 
and outlets were punched out of the device using blunt needles. To bond the device to a glass 
slide, both pieces were cleaned and then plasma treated. Once the device was sealed to the glass, 
it was placed in a 120 °C oven for a minimum of 15 minutes. Finally, to sterilize the device 
before experimentation, it was placed under ultraviolet light for 1 hour. 
4.3.2 Finite Element Modeling 
To understand the oxygen gradients achieved in our microfluidic device, a 3D model of mass and 
momentum transport was created in COMSOL Multiphysics 5.2a (Burlington, MA). First, 
understand the delivery of oxygen through the media lines, flow was modeled by solving the 
steady state solution of the incompressible Navier-Stokes equations using a no slip boundary 
condition for the walls. The different properties of the device are the same as those used 
previously (Table 1). The modeling of the 3D oxygen gradients is the same as previously 
described in Chapter 3.3.2. Briefly, the transport of diluted species module was used to mimic 
the transport of oxygen through the PDMS layer. Michaelis-Meten kinetics was used to model 
consumption of oxygen via cellular metabolism and the consumption of oxygen through the 
sodium sulfite reaction was based on previously reported findings in literature.52  
4.3.3 MDA-MB-231 Cell Culture 
Breast cancer cells, MDA-MB-231 cells, were purchased for this study from Cell Biolabs, Inc. 
(San Diego, CA) and grown in Dulbecco’s Modified Eagle Medium (DMEM, ThermoFisher, 
Waltham, MA) containing 10% fetal bovine serum (FBS, Sigma-Aldrich, St. Louis, MO), 1% L-
glutamine (ThermoFisher), and 1% penicillin streptomycin (ThermoFisher). Cells were cultured 
in a humidified incubator at 37 °C, 5% CO2, and 20% O2 before loaded into the microfluidic 
device.  
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4.3.4 HIF-1α Knockdown in MDA-MB-231 
For the scramble and shRNA HIF-1α lentiviral particle transduction (Santa Cruz Biotechnology, 
Dallas, TX), we first seeded MDA-MB-231 in a 24-well plate at a concentration of 4.5 x 104 
cells in each well and allowed to grow overnight to about 50% confluency. A 250 μl media 
solution containing 5 μg mL-1 polybrene (Santa Cruz Biotechnology) was added dropwise to 
each well. Next, a 250 μl solution of media and lentiviral particles at a dilution of 1:50 (v/v) 
particles to media or a multiplicity of infection (MOI) of about 1 was added to each well. The 
cells were allowed to incubate with the lentiviral particles for 18 hours before the media was 
changed. Stable clones expressing the scramble and shRNA lentiviral particles were selected via 
3 μg mL-1 concentration of puromycin dihydrochloride (Santa Cruz). These cells were then 
tested for HIF-1α gene expression by qRT-PCR and then frozen.  
To perform qRT-PCR, RNA was extracted and purified using the RNeasy Plus Mini Kit (Qiagen, 
Venlo, Netherlands) to a concentration of 100 ng μl-1. A reverse transcription kit (Applied 
Biosystems) was then used to convert the RNA to cDNA. HIF-1α gene expression was then 
measured using Taqman Gene Expression Assays (HIF-1α: Hs00154153_m1, 18S: 
Hs99999901_s1) using the CFX96 Real-Time PCR Detection System (Bio-Rad, Hercules, CA). 
Relative HIF-1α gene expression for control MDA-MB-231 (Control), scramble MDA-MB-231 
(Scramble), and shRNA HIF-1α MDA-MB-231 (shHIF-1α) were compared using the ΔΔCt 
method. 
4.3.5 Microfluidic Device Experiment 
The central chamber was first loaded with fibrin by resuspending 16 mg mL-1 fibrinogen (Sigma-
Aldrich) in Dubecco’s Phosphate Buffered Saline (DPBS, ThermoFisher) and mixing it with a 50 
U mL-1 thrombin solution. This initiates the polymerization process, at which time the mixture 
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was quickly pipetted into the central chamber. The gel was then incubated for 30 minutes at 37 
°C to ensure the polymerization process was complete. Next, the adjacent chambers were loaded 
with MDA-MB-231 cells at a concentration of 5 x 106 cells mL-1. The cells were mixed with the 
fibrinogen solution, and then this cell-fibrinogen solution was mixed with thrombin before 
pipetting it in to the left and right chambers. After complete polymerization of the fibrin gel, 
DMEM was flown through the media lines connected to the central chamber. The devices were 
then placed in a humidified incubator at 37 °C, 5% CO2, and 5% O2 overnight. The next day, the 
devices were imaged and the sodium sulfite was added to the left scavenger channel at varying 
concentrations. This treatment was applied for the next 6 days before stopping the experiment 
and performing a live/dead stain and imaging the devices.  
In this study, we performed 4 different chronic hypoxia (CH) and 2 different intermittent 
hypoxia (IH) studies. To achieve a range of different oxygen tensions, we varied the sodium 
sulfite concentrations. In the chronic hypoxia condition, we used 1mM (1CH), 2mM (2CH), 
3mM (3CH), and 5mM (5CH) concentrations of sodium sulfite. The solutions were placed in a 
syringe and tygon tubing (Saint-Gobain, Valley Forge, PA) was used to connect the syringe to 
the devices. For the duration of the experiment, the solutions were delivered continuously at a 
rate of 12 μl min-1 to maintain constant consumption of oxygen during the entire length of the 
experiment. Together, the concentration of sodium sulfite and the flow rate of the solution 
produced a mass flow rate that created a variety of desired oxygen gradients to affect the survival 
of shHIF-1α cells. The two intermittent hypoxia studies were intended to have the same temporal 
oxygen concentration average of the 1CH and 3CH conditions and were termed 1IH and 3IH 
respectively. Based on previous literature, we used a 1:1 ratio of time spent flowing scavenger to 
time with no scavenger flow.68,70 To ensure that 1IH had the same temporal oxygen 
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concentration average as 1CH, we used a concentration of 3mM sodium sulfite and flowed it for 
a total of 12 hours, before stopping flow for 12 hours. These calculations were based on the 
reaction kinetics of sodium sulfite. Similarly, in our 3IH condition, we used a sodium sulfite 
concentration of 9mM, and flowed it for a 1 hour cycle before stopping flow for an hour. 
Overall, we could test a variety of spatial and temporal oxygen gradients on Control, Scramble, 
and shHIF-1α cells. 
4.3.6 Tumor Growth and Migration Quantification  
To quantify the degree of tumor progression in our study, we split up this parameter into two 
factors: growth and migration. Images of the microfluidic device were taken before hypoxia 
treatment and at the end of the experiment. Each image was cropped to only contain the left, 
central, or right chamber, and the images were randomized and analyzed for tumor area using 
ImageJ. Tumor growth was defined as normalized tumor area (NTA), and is defined by the area 
in the left or right chamber on the final day of the experiment divided by the same chamber on 
day 1. The migration parameter we used was calculated by dividing the tumor area in the central 
chamber by the total tumor area in the left, central, and right chamber on the final day of the 
experiment. 
4.3.7 Statistical Analysis  
All conditions were performed using at least 3-6 biological replicates, and the results are 
represented as mean ± SD. A Mann-Whitney test was applied to compare tumor growth in the 
left and right chambers or migration parameter among shHIF-1α cells, Control or Scramble. 
Statistical significance was considered at the p < 0.05 level, and GraphPad Prism 6 was used for 
data analysis. 
37 
 
4.4 Results 
4.4.1 Microfluidic Device and Oxygen Concentration Profiles  
As we have shown previously, our microfluidic device can produce reliable pressure and velocity 
gradients to ensure the growth of the tissue inside the device. We were successfully able to 
observe tumor progression over the seven days of the experiment with the ability to quantify 
tumor growth as well as tumor migration.  
To understand the oxygen gradients we would achieve, we used extensive finite element 
modeling to predict the oxygen tension within the device (Fig. 4. 2). Various sodium sulfite 
concentrations were used in the models and demonstrate that by decreasing the concentration of 
scavenger, there is an attenuation of the oxygen gradient. The 1CH condition has an oxygen 
concentration rate of 4.93% to 5% O2. On the other hand, the 5CH condition has an oxygen 
concentration rate of 4.89% to 5% O2.  
 
 
O2(%) 
D A C B 
5CH 3CH 2CH 1CH 
Fig. 4. 2 Model of the oxygen distributions for various sodium sulfite concentrations. (A) 5CH, (B) 3CH, (C) 2CH, and 
(D) 1CH conditions show that decreasing the concentration of sodium sulfite attenuates the oxygen gradient in the 
device. 
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4.4.2 Response of MDA-MB-231 to Varying Oxygen Gradients 
The first experiment compared the growth of Control cells grown in 20% O2 to the more 
physiologically relevant 5% O2. We observed significantly more growth in 5% O2 compared to 
20% O2 (7.461 ± 4.64 NTA compared to 1.292 ± 0.86, respectively). In addition we observed 
significantly more migration in 5% O2 compared to 20% O2 (0.404 ± 0.184 compared to 0.008 ± 
0.004, respectively) (Fig. 4. 3A and B).  
 
Fig. 4. 3 There is enhanced tumor progression at 5% O2 compared to 20% 02 for Control MDA-MB-231 cells. (A) 
Images of representative devices in 20% (purple) vs. 5% O2 (green). (B) Quantification of normalized tumor area 
(left) and migration (right). *, p < 0.05; ****, p < 0.0001. Scale bar: 200 μm. 
Furthermore, when applying the oxygen gradient to the Control cells, there was no significant 
difference between the side that experienced the oxygen gradient (left) and the normoxia side 
(right). After flowing a 1mM sodium sulfite near the left tissue chamber, the left tissue chamber 
had a NTA of 6.4 ± 2.8 compared to the right chamber of 4.4 ± 1.9. Increasing the oxygen 
scavenger concentration to 2mM, the left and right chambers had a NTA of 5.8 ± 2.6 and 6.5 ± 
1.4 respectively. The 3 mM case had a NTA of 4.8 ± 2.6 in the left and 3.7 ± 1.2 in the right 
chamber. Lastly, increasing the sodium sulfite concentration to 5mM had a NTA of 4.6 ± 3.0 and 
6.3 ± 3.3 in the left and right chambers respectively. In all these conditions, there was no 
statistical significance between the left and right sides (Fig. 4. 4A).  
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Fig. 4. 4 Varying spatial and temporal gradients do not affect Control cell survival. (A) Chronic hypoxia conditions 
were defined by flowing varying concentrations of sodium sulfite from 1mM (1CH), 2mM (2CH), 3mM (3CH), and 
5mM (5CH). Normalized tumor area (NTA) was compared from the left chamber (blue, hypoxic side) to the right 
chamber (red, normoxic side). There was no statistical significance between the two sides (left graph). Images from 
each condition is shown on the right. The image in the left column is before the treatment of oxygen scavenger and 
the image in the right column is after the treatment. (B) Intermittent hypoxia conditions were defined to have the 
same temporal oxygen concentration gradient of flowing 1mM or 3mM of scavenger constantly (termed 1IH and 
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3IH respectively). Quantification of NTA (left graph) showed no statistical significance between the left (hypoxic) 
and right (normoxic side). Representative images of the experimental conditions are shown with images on the right. 
Scale bar: 200 μm. 
In addition, there was also no significant difference between the NTA of Control cells in the two 
sides of the device under the intermittent hypoxia conditions. The 1IH condition had a NTA of 
5.5 ± 2.0 and 6.0 ± 3.6 in the left and right chambers respectively. In the 3IH conditions, there 
was also no statistical significance in NTA between the left (4.2 ± 3.1) and right (4.3 ± 2.1) 
chambers (Fig. 4. 4B). 
4.4.3 Scramble and shHIF-1α Growth under Varying Oxygen Gradients 
After transducing the MDA-MB-231 cells with shRNA for HIF-1α, we observed an approximate 
60% knockdown of gene expression of HIF-1α in the shHIF-1α cells compared to Control (Fig. 
4. 5).  Knockdown of HIF-1α abrogated tumor cell growth at 5% oxygen such that there was no 
longer any difference in growth compared to 20%.  (NTA 1.8 ± 0.6 compared to 1.1 ± 0.3 for 
20% and 5% O2, respectively) (Fig. 4. 6A and B). Similarly, there was no difference in migration 
between 20% and 5% O2 (0.25 ± 0.16 and 0.09 ±0.11 respectively). 
 
Fig. 4. 5 Relative Gene Expression of Scramble and shRNA HIF-1α cells. Data from the qRT-PCR showed that 
knockdown cells had roughly a 60% reduced expression of HIF-1α. 
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Knockdown of HIF-1α significantly impacted the response to spatial and time varying oxygen 
concentration. First, there was no significant difference in tumor growth between the left and 
right side of the chambers for 0, 1mM, or 2mM sodium sulfite (Fig. 4. 7). 3mM sodium sulfite 
did not impact the Scramble cells (NTA of 3.7 ± 3.7 (left) and 4.0 ± 2.3 (right)); however, the 
tumor cells in the left side (lower oxygen) of the shHIF-1α demonstrated less growth (0.8 ± 0.2 
compared to 2.3 ± 0.9 in the left and right chambers, respectively, p < 0.05) (Fig. 4. 7D). A 
similar trend was observed at 5mM sodium sulfite (4.5 ± 1.3 and 5.1 ± 0.7 respectively for the 
Scramble, but 0.8 ± 0.7 and 3.0 ± 2.4 for the shHIF-1α, respectively, p < 0.01) (Fig. 4. 7E). 
Additionally, Fig. 4. 8 shows the percentage of tumor growth in the left and right chambers for 
the shHIF-1α cells. This was calculated by dividing the tumor area in the left or right chamber by 
the total tumor area in the final day of the experiment. The tumor growth of the shHIF-1α cells 
becomes severely impacted in the 3CH and 5CH conditions.  
A 
20
% 
5% 
Start End B 
O x y g e n  C o n c e n tra t io n
N
o
r
m
a
li
z
e
d
 T
u
m
o
r
 A
r
e
a
2 0 % 5 %
0
2
4
6
8
1 0
M
ig
r
a
ti
o
n
2 0 %  5 %
0 .0
0 .2
0 .4
0 .6
0 .8
1 .0
Fig. 4. 6 Knockdown of HIF-1α impacts tumor progression at normoxia (A) Images of devices in the 20% O2 (top) 
and 5% O2 (bottom) at the start (left column) and end (right column) of the experiment. (B) Quantification of NTA 
(left) and migration (right) shows no statistical difference between devices grown at 20% O2 (purple) or 5% O2 
(green) with shHIF-1α cells. 
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Fig. 4. 7 Various oxygen concentration gradients modulate the survival of MDA-MB-231 cells with a knockdown of 
HIF-1α. (A-E) Quantification of NTA for Scramble and shHIF-1α in various chronic hypoxia conditions (top graph). 
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Scramble (left) and shHIF-1α (right) images before (top) and after (bottom) treatment are shown below. (A) 
Normoxia had no statistical difference between the left and right chambers for both the Scramble and shHIF-1α 
cells. (B) 1CH and (C) 2CH also had no statistical difference between the left and right chambers. (D) At 3CH, 
Scramble had no statistical difference between the two chambers, but shHIF-1α had statistically less growth in the 
left (hypoxic) chamber compared to the right. (E) 5CH had no statistical difference between the left and right 
chambers for the Scramble cells, but had statistically significant difference between the two for the shHIF-1α cells. 
Left chambers are represented in blue and right chambers are represented in red for Scramble (cross) and shHIF-1α 
(blank) cells. *, p < 0.05; **, p < .01. Scale bar = 200 μm. 
 
 
 
The cycles of intermittent hypoxia were performed to produce an oxygen tension with a temporal 
average similar to the 1mM or 3mM CH condition. These conditions are termed 1IH and 3IH, 
respectively. For our conditions, we used a ratio of 1:1 for the duration of applying the scavenger 
to stopping the flow of scavenger. For 1IH, we applied long 12 hour cycles and saw no 
significant difference between the two sides of the Scramble case (NTA of 3.4 ± 2.5 and 4.1 ± 
1.2, respectively, for the left and right side of the device). However, with this longer 12 hour 
cycle duration, we saw a significant difference between the left and right sides of the device in 
the shHIF-1α case (NTA of 0.4 ± 0.2 and 2.1 ± 0.9, respectively, p < 0.05) (Fig. 4. 9A). With the 
3IH condition, we used shorter 1 hour cycles of alternating scavenger flow and no flow. In this 
Fig. 4. 8 Percent tumor growth of shHIF-1α. As the concentration of sodium sulfite increases, the 
more it impacts the tumor cell growth in the left chamber. At 3CH and 5CH conditions, this 
impact becomes significant. 
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case, we saw no significant difference in either the Scramble (NTA of 4.3 ± 0.9 and 4.3 ± 1.0 for 
the left and right sides, respectively) or the shHIF-1α condition (NTA of 3.0 ± 2.6 (left) and 3.7 
± 2.5 (right)) (Fig. 4. 9B).   
 
Fig. 4. 9 Temporal variations in oxygen tension affect the survival of shHIF-1α cells. (A-B) NTA is shown in the 
upper graph, while representative images are shown below. (A) In the 1IH case, there was no statistical significance 
between the growth in the left or right chambers of the Scramble cells. There was statistical significance in growth 
between the left and right chambers for the shHIF-1α cells. (B) The 3IH condition had no statistical difference 
between the left and right chambers in the Scramble and shHIF-1α cells. Left chambers are represented in blue and 
right chambers are represented in red for Scramble (cross) and shHIF-1α (blank) cells. *, p < 0.05. Scale bar = 200 
μm. 
4.4.4 Migration parameter during hypoxic conditions  
In addition to tumor growth, we measured tumor migration into the central chamber (Fig. 4. 10). 
The Control cells had relatively similar migration values over all the conditions (averaging 0.42 
± 0.18). In contrast, shHIF-1α cells had more variable migration values. Starting with normoxia, 
the shHIF-1α cells had a migration parameter of 0.14 ± 0.09. The 5CH condition had no 
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migration and the 3IH condition had the most migration with a value of 0.136 ± 0.19. Overall, 
the Control cells had significantly more migration than the shHIF-1α cells except for the 4IH 
condition, which had a p-value of 0.06. Lastly, the Scramble cells had similar migration values to 
the Control cells with an average value of 0.3 ± 0.19 over all the conditions. There was no 
significant difference between the Control and Scramble migration values.  
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Fig. 4. 10 Knockdown of HIF-1α impacts the migration of MDA-MB-231 cells. Quantification of migration for each 
oxygen gradient condition for the Control (black), Scramble (crisscross), and shHIF-1α (white) cells. In all 
conditions except for 3IH, the Control cells had statistically significant more migration than shHIF-1α (*, p < 0.05 
and ***, p < .001). 
4.5 Discussion 
As organ-on-a-chip technologies have become more advanced, there is a growing interest to 
replicate disease states.77 However, disease states can be difficult to recapitulate due to their 
complexity relative to normal physiology. During tumor progression, the rapid growth of tumor 
cells requires an expanding vessel network to provide nutrients and oxygen to the growing 
mass.10 However, the resulting vessel network is often leaky and tortuous.78 This difference in 
vasculature network can lead to abnormal temporal and spatial oxygen gradients, and those 
tumor cells that can persist in hypoxic microenvironments have been shown to be resistant to 
traditional cancer treatments. Our study presents the design, fabrication, and testing of a 
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microfluidic device that can control oxygen gradients both spatially and temporally. We have 
shown that this device can be used to investigate mechanisms of hypoxia, such as the role of 
HIF-1α in modulating temporal dynamics of oxygen concentration.  
Our initial observation that MDA-MB-231 breast cancer cells have more growth and migration 
in 5% O2 than 20% O2 suggests that these cells have adapted to have a survival advantage at a 
normoxic oxygen tension.  Knocking down HIF-1α completely abrogates this growth advantage 
suggesting that MDA-MB-231 cells have a higher level of HIF-1α at normoxic oxygen levels.    
To begin to understand the mechanisms that contribute to an enhanced level of HIF-1α, we 
applied varying spatial and temporal oxygen gradients to Control, Scramble and shHIF-1α cells.  
Our results for chronic hypoxia (not temporal variation) show that an observable change in tumor 
cell growth can be detected within a very small range of oxygen tensions.  There was no 
detectable change in growth at 2 mM sodium sulfite (mean oxygen tension in the scavenger side 
tumor chamber of 4.93%), yet 3mM sodium sulfite (mean oxygen tension in the scavenger side 
tumor chamber of 4.90%) produced a significant reduction in growth.  In other words, HIF-1α 
provides a threshold oxygen concentration for enhanced MDA-MB-231 cancer cell growth.  
Using equal cycles of scavenger flow and no flow, we chose intermittent hypoxic conditions that 
have the same temporal average of 1CH and 3CH conditions. We chose these conditions because 
they were near the threshold of showing no bias (1CH) or significant bias (3CH) between the left 
and right shHIF-1α tissue chambers. Interestingly, although 1CH showed no variance between 
the two sides, 1IH showed a significant difference between the left and right chambers.  Under 
this condition, a long cycle (12 hours) of 3mM scavenger flow followed by no flow was 
adequate to induce a similar response of a constant 3mM sodium sulfite.  In contrast, even 
though 3CH had significant variation in tumor growth between the left and right chambers in the 
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shHIF-1α condition, by choosing a relatively short cycle of 1 hour of scavenger flow and no 
flow, the 3IH condition showed no significant difference.  This is interesting because although 
the temporal average oxygen concentration is the same between the corresponding chronic and 
intermittent hypoxia conditions, the outcomes from the shHIF-1α differ in these two cases. This 
result provides some insight into the necessary duration of hypoxia at the level of 4.9% to impact 
cell proliferation:  the duration should be longer than 1 hour, and 12 hours is adequate.    
Lastly, we quantified a migration parameter between the Control, Scramble, and shHIF-1α. We 
found that there was statistically more tumor migration in the Control cells than shHIF-1α in 
every condition except for 3IH, which had p-value of 0.06. This is consistent with previous 
studies that show that HIF-1α stimulates tumor migration.79,80 While we didn’t see any trends in 
tumor migration between the different hypoxic conditions, it would be of interest to use different 
fluorescent MDA-MB-231 cells in the left and right chambers to identify if more cells were 
migrating from the left (hypoxic) chamber or the right (normoxia) chamber.  
4.6 Conclusions 
The aim of this study was to demonstrate the need to more accurately recapitulate the tumor 
microenvironment for effective drug testing. We chose to control oxygen tension both 
temporally and spatially and then examined tumor cell proliferation and migration -- indices of 
tumor progression. While an attractive target of tumor hypoxia is HIF-1α, we have demonstrated 
that the spatial and temporal complexities of the oxygen environment can potentially undermine 
this strategy. Because the microfluidic device design we used has the ability to measure tumor 
growth and migration throughout the length of the experiment, we were able to quantify tumor 
progression over the course of oxygen treatment. Overall, we believe this microfluidic design is 
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flexible enough to recapitulate some of the intricacies of the tumor microenvironment to give us 
the opportunity to study tumor behavior under varying oxygen tensions. 
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Chapter 5: Conclusions and Future 
Directions  
Since the first discovery of the cause of a cancer in 1731, many advancements have been made to 
understand this disease.81 However, with each new discovery, we uncover so much more that we 
do not understand. This creates many problems while trying to discover and test new cancer 
treatments. Therefore, it is critical for scientists to develop platforms that can best recreate the 
tumor microenvironment for both research and drug innovation applications.  
5.1 Tumor-on-a-chip Systems 
Microengineered physiological systems have become a promising technology for drug testing as 
well as studying tumor biology.82 Due to its inherent small size, this approach reduces reagent 
requirements which facilitates high-throughput testing, which is critical for anticancer drug pre-
screening applications. In addition, because most microphysiological systems are developed 
using a clear plastic, researchers have the opportunity to watch tumor progression in terms of 
growth, invasion, and metastasis in real time.83 This provides a huge advantage over animal 
models, which is the current gold standard. While animal models can sustain complex tumor 
microenvironments, it is unclear how accurately it can model human tumorigenesis.84 Thus, there 
is great interest in developing better tumor models. 
The tumor microenvironment consists of a complex mixture of cellular and non-cellular 
components. The surrounding environment can include blood vessels, carcinoma associated 
fibroblasts (CAFs), immune cells, and the extracellular matrix. It has become increasingly 
recognized that the key to developing cancer treatments is our ability to recapitulate these aspects 
of the tumor microenvironment. Recent studies have shown that the interaction between tumor 
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cells and microenvironment has profound effects on the tumor’s behavior and drug 
resistance.85,86 Many advancements have been made towards including the heterogeneous 
mixture of cell types in the tumor microenvironment. Qin’s research lab used the high spatial 
control of microfluidic devices to study how CAFs promote tumor spheroid invasion.87 Jeon’s 
research group has developed a method for studying the process of tumor angiogenesis and how 
tumor cells interact with the blood vessel network, which has implications for understanding 
tumor metastasis.88 Furthermore, Businaro’s research group has studied the interaction between 
tumor cells and the immune system to observe that the tumor cells can direct the migration of the 
immune cells.89 Together, these groups have demonstrated that microphysiological systems can 
incorporate multiple cell types to study their interaction during tumor progression. 
Another important aspect to replicate in the tumor microenvironment is the tumor cells 
interaction with non-cellular components. Often, this consists of mimicking the extracellular 
matrix that’s present in the tumor microenvironment. It has been known that the matrix stiffness 
increases in the tumor microenvironment. These parameters are easily modulated in 
microengineered physiological systems, and Weaver’s research group has shown that by 
replicating the increased stiffness of the extracellular matrix of the tumor microenvironment, it 
promotes a more malignant behavior by modulating integrins, which is critical for our 
understanding of cancer cell migration.90 Other studies have looked at how chemical gradients 
affect tumor behavior.59,91 However, an important aspect of tumor biology to replicate is tumor 
hypoxia, which has been proven to be difficult to model.  
5.2 Hypoxia Disease Modelling  
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Several strategies have been used to mimic hypoxia for disease modelling. One strategy from 
Gerecht’s lab has been to develop a hydrogel that consumes oxygen in situ.92  They have shown 
that their hypoxic hydrogels can promote neovascularization from a host tissue during 
subcutaneous wound healing.92 McGuigan’s lab discovered a method of turning two-dimensional 
cell cultures in to three-dimensional models of tumors by rolling a scaffold-tumor strip into a 
cylinder. A gradient of oxygen then forms from the outside of the cylinder towards the center as 
it is diffusion limited. By unrolling the strip, the research team showed that they were able to 
understand the spatial mapping of cell metabolism within a tumor sphere.93 Another method of 
modelling tumor hypoxia comes from the Whitesides’ lab and was termed Cells-in-Gels-in-Paper 
(CiGiP). This method employs the layering of stacks of paper containing cells encapsulated in a 
gel with the lower layers receiving less oxygen and nutrients than the top layers. The research 
team identified that after deconstruction of the different layers, the bottom (hypoxic) cells were 
more resistant to irradiation treatment.94  
A trend for studying hypoxia has been to use microfluidic devices. With inherently small 
features, there are very short diffusion times to manipulate oxygen tension. As mentioned in 
Chapter 2, there are several strategies that employ microfluidic devices to control oxygen 
gradients. Most include using a dedicated line for an oxygen sink to draw oxygen away from the 
tissue chamber. This can be nitrogen gas, a chemical reaction, or another cell type consuming 
oxygen. Chapters 3 and 4 detail a method of using sodium sulfite as a scavenger to control the 
spatial and temporal gradients of oxygen. For all of these designs, an important consideration for 
choosing an oxygen scavenger is the reaction rate. Because we wanted to switch the flow of 
scavenger on and off quickly, we chose a scavenger that can react with oxygen quickly. 
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5.3 Future Directions 
Over the past 5 years, there has been increasing interest in using microphysiological systems to 
resolve some of the critical issues in drug development. The more we can advance these models 
of the human body, the more applicable they become to studying human physiology and 
pathology. In the future, as more accurate models of tumor hypoxia become available, we can 
begin to study how tumor metabolism adapts to these pressures. The ability for cancer cells to 
alter their metabolism is one of the reasons tumors can thrive during hypoxia, and these changes 
are now considered one of the hallmark features of cancer.95 This understanding of tumor 
metabolism during hypoxia can give researchers new therapeutic targets. Furthermore, by 
creating an accurate microfluidic device of tumor hypoxia, we can use this platform as a high 
throughput method of testing the effectiveness of drugs to target hypoxia cancer cells. As these 
are understood to be the hardest cells to target, developing an accurate model for tumor hypoxia 
can help resolve these issues. While many challenges remain for developing chronic and 
intermittent hypoxia, there remains growing interest to address these challenges and present new 
and exciting opportunities for improved anticancer therapies.  
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